Annual EBITDA
$8.00 B
-$33.03 B-80.50%
31 December 2023
Summary:
Pfizer annual earnings before interest, taxes, depreciation & amortization is currently $8.00 billion, with the most recent change of -$33.03 billion (-80.50%) on 31 December 2023. During the last 3 years, it has fallen by -$5.26 billion (-39.68%). PFE annual EBITDA is now -80.50% below its all-time high of $41.03 billion, reached on 31 December 2022.PFE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$6.81 B
+$4.40 B+183.04%
30 September 2024
Summary:
Pfizer quarterly earnings before interest, taxes, depreciation & amortization is currently $6.81 billion, with the most recent change of +$4.40 billion (+183.04%) on 30 September 2024. Over the past year, it has increased by +$7.91 billion (+720.78%). PFE quarterly EBITDA is now -47.27% below its all-time high of $12.91 billion, reached on 01 June 2022.PFE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$13.39 B
+$7.91 B+144.16%
30 September 2024
Summary:
Pfizer TTM earnings before interest, taxes, depreciation & amortization is currently $13.39 billion, with the most recent change of +$7.91 billion (+144.16%) on 30 September 2024. Over the past year, it has dropped by -$5.00 billion (-27.18%). PFE TTM EBITDA is now -67.36% below its all-time high of $41.03 billion, reached on 31 December 2022.PFE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PFE EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -80.5% | +720.8% | -27.2% |
| 3 y3 years | -39.7% | -28.4% | -51.2% |
| 5 y5 years | -27.7% | -46.3% | -23.5% |
PFE EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -80.5% | at low | -47.3% | +484.5% | -67.4% | +144.2% |
| 5 y | 5 years | -80.5% | at low | -47.3% | +207.7% | -67.4% | +179.7% |
| alltime | all time | -80.5% | +733.1% | -47.3% | +191.3% | -67.4% | +709.7% |
Pfizer EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $6.81 B(+183.0%) | $13.39 B(+144.2%) |
| June 2024 | - | $2.41 B(-59.5%) | $5.49 B(-26.2%) |
| Mar 2024 | - | $5.95 B(-435.8%) | $7.43 B(-22.3%) |
| Dec 2023 | $8.00 B(-80.5%) | -$1.77 B(+61.4%) | $9.56 B(-48.0%) |
| Sept 2023 | - | -$1.10 B(-125.2%) | $18.39 B(-38.7%) |
| June 2023 | - | $4.35 B(-46.1%) | $29.98 B(-22.2%) |
| Mar 2023 | - | $8.07 B(+14.3%) | $38.55 B(-6.1%) |
| Dec 2022 | $41.03 B(+33.2%) | $7.06 B(-32.7%) | $41.03 B(+4.0%) |
| Sept 2022 | - | $10.49 B(-18.7%) | $39.45 B(+2.6%) |
| June 2022 | - | $12.91 B(+22.3%) | $38.46 B(+12.7%) |
| Mar 2022 | - | $10.56 B(+92.8%) | $34.12 B(+10.8%) |
| Dec 2021 | $30.79 B(+132.2%) | $5.48 B(-42.4%) | $30.80 B(+12.1%) |
| Sept 2021 | - | $9.51 B(+10.9%) | $27.47 B(+36.8%) |
| June 2021 | - | $8.57 B(+18.5%) | $20.08 B(+24.7%) |
| Mar 2021 | - | $7.24 B(+236.7%) | $16.10 B(+21.4%) |
| Dec 2020 | $13.26 B(-28.9%) | $2.15 B(+1.2%) | $13.26 B(+177.0%) |
| Sept 2020 | - | $2.12 B(-53.8%) | $4.79 B(-68.8%) |
| June 2020 | - | $4.59 B(+4.4%) | $15.35 B(-8.7%) |
| Mar 2020 | - | $4.40 B(-169.5%) | $16.82 B(-9.8%) |
| Dec 2019 | $18.65 B(+68.6%) | -$6.33 B(-149.8%) | $18.65 B(+6.5%) |
| Sept 2019 | - | $12.69 B(+109.5%) | $17.52 B(+60.3%) |
| June 2019 | - | $6.06 B(-2.7%) | $10.93 B(-3.2%) |
| Mar 2019 | - | $6.23 B(-183.5%) | $11.29 B(+2.0%) |
| Dec 2018 | $11.06 B(-44.3%) | -$7.46 B(-222.3%) | $11.06 B(-48.3%) |
| Sept 2018 | - | $6.10 B(-4.9%) | $21.38 B(+3.0%) |
| June 2018 | - | $6.42 B(+6.8%) | $20.75 B(+3.6%) |
| Mar 2018 | - | $6.00 B(+110.1%) | $20.03 B(+1.0%) |
| Dec 2017 | $19.84 B(+29.8%) | $2.86 B(-47.8%) | $19.84 B(+1.2%) |
| Sept 2017 | - | $5.47 B(-4.0%) | $19.61 B(+12.5%) |
| June 2017 | - | $5.70 B(-2.0%) | $17.43 B(+10.2%) |
| Mar 2017 | - | $5.82 B(+121.8%) | $15.82 B(+3.4%) |
| Dec 2016 | $15.29 B(-0.2%) | $2.62 B(-20.3%) | $15.29 B(+8.6%) |
| Sept 2016 | - | $3.29 B(-19.5%) | $14.08 B(-6.4%) |
| June 2016 | - | $4.09 B(-22.7%) | $15.03 B(-5.8%) |
| Mar 2016 | - | $5.29 B(+276.7%) | $15.96 B(+4.2%) |
| Dec 2015 | $15.32 B(-19.9%) | $1.41 B(-66.9%) | $15.32 B(-12.0%) |
| Sept 2015 | - | $4.25 B(-15.4%) | $17.40 B(-5.5%) |
| June 2015 | - | $5.02 B(+7.9%) | $18.41 B(-3.9%) |
| Mar 2015 | - | $4.65 B(+33.4%) | $19.16 B(+0.1%) |
| Dec 2014 | $19.14 B(-18.7%) | $3.49 B(-33.7%) | $19.14 B(-6.9%) |
| Sept 2014 | - | $5.26 B(-8.9%) | $20.55 B(-0.9%) |
| June 2014 | - | $5.77 B(+24.8%) | $20.73 B(-7.0%) |
| Mar 2014 | - | $4.62 B(-5.6%) | $22.29 B(-5.3%) |
| Dec 2013 | $23.54 B(+15.3%) | $4.90 B(-9.9%) | $23.54 B(+1.5%) |
| Sept 2013 | - | $5.43 B(-26.0%) | $23.20 B(+2.6%) |
| June 2013 | - | $7.34 B(+25.0%) | $22.61 B(+5.2%) |
| Mar 2013 | - | $5.87 B(+28.8%) | $21.50 B(+4.0%) |
| Dec 2012 | $20.42 B(-8.0%) | $4.56 B(-5.9%) | $20.68 B(+1.8%) |
| Sept 2012 | - | $4.84 B(-22.3%) | $20.30 B(-6.2%) |
| June 2012 | - | $6.23 B(+23.4%) | $21.64 B(+0.4%) |
| Mar 2012 | - | $5.05 B(+20.5%) | $21.55 B(-2.9%) |
| Dec 2011 | $22.19 B(+12.8%) | $4.19 B(-32.3%) | $22.18 B(+3.9%) |
| Sept 2011 | - | $6.18 B(+0.7%) | $21.34 B(+11.0%) |
| June 2011 | - | $6.13 B(+8.0%) | $19.23 B(-2.0%) |
| Mar 2011 | - | $5.68 B(+69.7%) | $19.63 B(-0.2%) |
| Dec 2010 | $19.67 B(+16.9%) | $3.35 B(-17.8%) | $19.67 B(+6.0%) |
| Sept 2010 | - | $4.07 B(-37.7%) | $18.56 B(-6.3%) |
| June 2010 | - | $6.53 B(+14.1%) | $19.80 B(+10.9%) |
| Mar 2010 | - | $5.72 B(+155.2%) | $17.86 B(+2.0%) |
| Dec 2009 | $16.82 B(+9.9%) | $2.24 B(-57.8%) | $17.50 B(+11.6%) |
| Sept 2009 | - | $5.31 B(+15.8%) | $15.68 B(+1.9%) |
| June 2009 | - | $4.59 B(-14.5%) | $15.39 B(+1.1%) |
| Mar 2009 | - | $5.37 B(+1183.5%) | $15.22 B(+0.5%) |
| Dec 2008 | $15.30 B(-1.5%) | $418.00 M(-91.7%) | $15.14 B(-17.8%) |
| Sept 2008 | - | $5.02 B(+13.5%) | $18.42 B(+18.0%) |
| June 2008 | - | $4.42 B(-16.4%) | $15.60 B(+5.4%) |
| Mar 2008 | - | $5.29 B(+43.2%) | $14.81 B(-4.7%) |
| Dec 2007 | $15.54 B(-20.6%) | $3.69 B(+67.6%) | $15.54 B(-1.1%) |
| Sept 2007 | - | $2.20 B(-39.2%) | $15.71 B(-16.0%) |
| June 2007 | - | $3.62 B(-39.8%) | $18.70 B(-6.1%) |
| Mar 2007 | - | $6.02 B(+55.7%) | $19.93 B(+1.8%) |
| Dec 2006 | $19.57 B(-1.0%) | $3.86 B(-25.7%) | $19.57 B(-4.8%) |
| Sept 2006 | - | $5.20 B(+7.2%) | $20.55 B(+1.4%) |
| June 2006 | - | $4.85 B(-14.4%) | $20.28 B(+1.0%) |
| Mar 2006 | - | $5.66 B(+16.9%) | $20.08 B(+0.6%) |
| Dec 2005 | $19.78 B(-8.1%) | $4.84 B(-1.6%) | $19.95 B(-2.8%) |
| Sept 2005 | - | $4.92 B(+5.9%) | $20.51 B(-3.6%) |
| June 2005 | - | $4.65 B(-16.0%) | $21.28 B(-1.0%) |
| Mar 2005 | - | $5.54 B(+2.3%) | $21.50 B(-0.1%) |
| Dec 2004 | $21.52 B | $5.41 B(-4.9%) | $21.52 B(+4.9%) |
| Sept 2004 | - | $5.69 B(+16.8%) | $20.51 B(+10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2004 | - | $4.87 B(-12.2%) | $18.51 B(+12.6%) |
| Mar 2004 | - | $5.55 B(+26.0%) | $16.44 B(+12.2%) |
| Dec 2003 | $14.39 B(+8.5%) | $4.40 B(+19.5%) | $14.65 B(+3.5%) |
| Sept 2003 | - | $3.69 B(+31.5%) | $14.15 B(+2.7%) |
| June 2003 | - | $2.80 B(-25.5%) | $13.78 B(+0.6%) |
| Mar 2003 | - | $3.76 B(-3.6%) | $13.70 B(+3.3%) |
| Dec 2002 | $13.26 B(+14.4%) | $3.90 B(+17.7%) | $13.26 B(+10.7%) |
| Sept 2002 | - | $3.31 B(+22.1%) | $11.97 B(+1.9%) |
| June 2002 | - | $2.72 B(-18.3%) | $11.75 B(-1.2%) |
| Mar 2002 | - | $3.32 B(+26.9%) | $11.88 B(+2.4%) |
| Dec 2001 | $11.59 B(+21.5%) | $2.62 B(-15.2%) | $11.60 B(+0.1%) |
| Sept 2001 | - | $3.09 B(+8.2%) | $11.60 B(+5.6%) |
| June 2001 | - | $2.85 B(-6.2%) | $10.98 B(+7.3%) |
| Mar 2001 | - | $3.04 B(+16.4%) | $10.23 B(+7.0%) |
| Dec 2000 | $9.54 B(+21.2%) | $2.61 B(+5.7%) | $9.56 B(+4.7%) |
| Sept 2000 | - | $2.47 B(+17.5%) | $9.13 B(+8.0%) |
| June 2000 | - | $2.10 B(-11.5%) | $8.46 B(+1.1%) |
| Mar 2000 | - | $2.38 B(+8.9%) | $8.37 B(+15.0%) |
| Dec 1999 | $7.87 B(+28.0%) | $2.18 B(+21.2%) | $7.28 B(-9.0%) |
| Sept 1999 | - | $1.80 B(-10.7%) | $7.99 B(+8.2%) |
| June 1999 | - | $2.01 B(+56.8%) | $7.39 B(+15.1%) |
| Mar 1999 | - | $1.28 B(-55.7%) | $6.42 B(+4.1%) |
| Dec 1998 | $6.15 B(+75.6%) | $2.90 B(+143.0%) | $6.17 B(+49.8%) |
| Sept 1998 | - | $1.19 B(+14.1%) | $4.12 B(+6.1%) |
| June 1998 | - | $1.04 B(+1.4%) | $3.88 B(+6.0%) |
| Mar 1998 | - | $1.03 B(+21.7%) | $3.66 B(-0.4%) |
| Dec 1997 | $3.50 B(+12.9%) | $847.00 M(-11.2%) | $3.67 B(+10.0%) |
| Sept 1997 | - | $954.00 M(+15.4%) | $3.34 B(+0.5%) |
| June 1997 | - | $827.00 M(-20.8%) | $3.32 B(+4.6%) |
| Mar 1997 | - | $1.04 B(+103.1%) | $3.17 B(+4.4%) |
| Dec 1996 | $3.10 B(+5.7%) | $514.00 M(-45.1%) | $3.04 B(-8.1%) |
| Sept 1996 | - | $937.00 M(+37.8%) | $3.31 B(+5.1%) |
| June 1996 | - | $680.00 M(-25.3%) | $3.15 B(+1.7%) |
| Mar 1996 | - | $910.00 M(+16.4%) | $3.10 B(+5.6%) |
| Dec 1995 | $2.93 B(+29.6%) | $781.60 M(+0.6%) | $2.93 B(+7.3%) |
| Sept 1995 | - | $776.70 M(+23.9%) | $2.73 B(+7.7%) |
| June 1995 | - | $626.90 M(-16.0%) | $2.54 B(+6.7%) |
| Mar 1995 | - | $746.50 M(+28.4%) | $2.38 B(+4.9%) |
| Dec 1994 | $2.26 B(+93.3%) | $581.30 M(+0.1%) | $2.27 B(+61.2%) |
| Sept 1994 | - | $581.00 M(+24.4%) | $1.41 B(+5.0%) |
| June 1994 | - | $466.90 M(-26.7%) | $1.34 B(-10.1%) |
| Mar 1994 | - | $636.60 M(-328.5%) | $1.49 B(+6.2%) |
| Dec 1993 | $1.17 B(-31.4%) | -$278.60 M(-154.2%) | $1.40 B(-33.3%) |
| Sept 1993 | - | $514.20 M(-16.6%) | $2.10 B(+2.1%) |
| June 1993 | - | $616.80 M(+12.2%) | $2.06 B(+15.6%) |
| Mar 1993 | - | $549.90 M(+30.3%) | $1.78 B(+4.4%) |
| Dec 1992 | $1.71 B(+14.0%) | $422.00 M(-10.6%) | $1.71 B(+6.3%) |
| Sept 1992 | - | $471.90 M(+39.2%) | $1.61 B(+2.4%) |
| June 1992 | - | $338.90 M(-28.6%) | $1.57 B(+2.0%) |
| Mar 1992 | - | $474.50 M(+48.0%) | $1.54 B(+2.7%) |
| Dec 1991 | $1.50 B(+17.1%) | $320.50 M(-26.3%) | $1.50 B(+3.7%) |
| Sept 1991 | - | $434.80 M(+40.8%) | $1.44 B(+3.6%) |
| June 1991 | - | $308.70 M(-28.9%) | $1.39 B(+3.2%) |
| Mar 1991 | - | $434.00 M(+62.6%) | $1.35 B(+5.6%) |
| Dec 1990 | $1.28 B(+8.8%) | $266.90 M(-30.7%) | $1.28 B(-158.3%) |
| Sept 1990 | - | $385.20 M(+45.2%) | -$2.20 B(+92.1%) |
| June 1990 | - | $265.20 M(-26.8%) | -$1.14 B(+982.5%) |
| Mar 1990 | - | $362.50 M(-111.3%) | -$105.60 M(-110.9%) |
| Dec 1989 | $1.18 B(-2.6%) | -$3.21 B(-323.1%) | $968.20 M(-17.4%) |
| Sept 1989 | - | $1.44 B(+10.4%) | $1.17 B(+5.0%) |
| June 1989 | - | $1.30 B(-9.3%) | $1.12 B(-2.9%) |
| Mar 1989 | - | $1.44 B(-147.8%) | $1.15 B(+13.7%) |
| Dec 1988 | $1.21 B(+9.4%) | -$3.01 B(-317.3%) | $1.01 B(-23.0%) |
| Sept 1988 | - | $1.38 B(+3.5%) | $1.31 B(+6.9%) |
| June 1988 | - | $1.34 B(+3.0%) | $1.23 B(+9.8%) |
| Mar 1988 | - | $1.30 B(-148.0%) | $1.12 B(+19.0%) |
| Dec 1987 | $1.10 B(-0.4%) | -$2.70 B(-308.3%) | $940.80 M(-27.1%) |
| Sept 1987 | - | $1.30 B(+5.8%) | $1.29 B(+11.7%) |
| June 1987 | - | $1.23 B(+9.6%) | $1.16 B(+10.4%) |
| Mar 1987 | - | $1.12 B(-147.6%) | $1.05 B(+9.1%) |
| Dec 1986 | $1.11 B(+9.6%) | -$2.35 B(-302.3%) | $959.70 M(-21.8%) |
| Sept 1986 | - | $1.16 B(+4.0%) | $1.23 B(+14.0%) |
| June 1986 | - | $1.12 B(+8.3%) | $1.08 B(+12.1%) |
| Mar 1986 | - | $1.03 B(-149.5%) | $960.20 M(+9.9%) |
| Dec 1985 | $1.01 B(+5.1%) | -$2.09 B(-306.0%) | $873.80 M(-3.5%) |
| Sept 1985 | - | $1.01 B(+1.1%) | $905.70 M(+3.4%) |
| June 1985 | - | $1.00 B(+5.9%) | $875.60 M(+1.9%) |
| Mar 1985 | - | $945.70 M(-146.0%) | $859.40 M(+3.1%) |
| Dec 1984 | $960.30 M | -$2.05 B(-309.1%) | $833.50 M(-71.1%) |
| Sept 1984 | - | $982.70 M(-0.3%) | $2.89 B(+51.6%) |
| June 1984 | - | $985.70 M(+7.2%) | $1.91 B(+107.2%) |
| Mar 1984 | - | $919.80 M | $919.80 M |
FAQ
- What is Pfizer annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Pfizer?
- What is Pfizer annual EBITDA year-on-year change?
- What is Pfizer quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Pfizer?
- What is Pfizer quarterly EBITDA year-on-year change?
- What is Pfizer TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Pfizer?
- What is Pfizer TTM EBITDA year-on-year change?
What is Pfizer annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PFE is $8.00 B
What is the all time high annual EBITDA for Pfizer?
Pfizer all-time high annual earnings before interest, taxes, depreciation & amortization is $41.03 B
What is Pfizer annual EBITDA year-on-year change?
Over the past year, PFE annual earnings before interest, taxes, depreciation & amortization has changed by -$33.03 B (-80.50%)
What is Pfizer quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PFE is $6.81 B
What is the all time high quarterly EBITDA for Pfizer?
Pfizer all-time high quarterly earnings before interest, taxes, depreciation & amortization is $12.91 B
What is Pfizer quarterly EBITDA year-on-year change?
Over the past year, PFE quarterly earnings before interest, taxes, depreciation & amortization has changed by +$7.91 B (+720.78%)
What is Pfizer TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PFE is $13.39 B
What is the all time high TTM EBITDA for Pfizer?
Pfizer all-time high TTM earnings before interest, taxes, depreciation & amortization is $41.03 B
What is Pfizer TTM EBITDA year-on-year change?
Over the past year, PFE TTM earnings before interest, taxes, depreciation & amortization has changed by -$5.00 B (-27.18%)